Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q1 2015 · 10-Q
Revenue$5.17M$5.17M+119.1% vs Q1 2014 Net Income-$10.58M-$10.58MN/M vs Q1 2014 EPS Diluted-$0.18-$0.18N/M vs Q1 2014 Operating Income-$8,367,611N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
Free Cash Flowderived-$12,595,229N/M Margins · derivedOperating margin-162.0%+262.2 pt vs Q1 2014
Net margin-204.8%+254.2 pt vs Q1 2014
ended Mar 31, 2015 · filed May 11, 2015 · 41 d after period end